

104. (New) The method of claim 31, in which the protein is not more than 50 amino acids in length and includes, positioned anywhere along its sequence, the contiguous amino acid sequence of: DSDVRRPW (SEQ ID NO:260) or AADQRRGW (SEQ ID NO:261) or DGRGGRSY (SEQ ID NO:262).

105. (New) The method of claim 31, in which the protein is not more than 50 amino acids in length and includes, positioned anywhere along its sequence, the contiguous amino acid sequence of: RVRS (SEQ ID NO:263) or SVRSGCGFRGSS (SEQ ID NO:264) or SVRGGCGAHSS (SEQ ID NO:265).

106. (New) The method of claim 100, 101, 102, 103, 104, or 105, wherein the protein is not more than 40 amino acids in length.

107. (New) The method of claim 100, 101, 102, 103, 104, or 105, wherein the protein is not more than 30 amino acids in length.

108. (New) The method of claim 100, 101, 102, 103, 104, or 105, wherein the protein is not more than 20 amino acids in length.

---


#### **REMARKS**

Claims 1-30, 40-74 and 76-97 have been canceled without prejudice as being drawn to non-elected inventions.<sup>1</sup> Applicants reserve the right to prosecute the subject matter of the canceled claims in related applications.

Claims 31-33 and 75 have been amended, and new claims 98-108 have been added, to more particularly point out and distinctly claim the subject matter which Applicants regard as their invention. Support for the amended and new claims can be found in the specification as originally filed as set forth in the chart below.

---

<sup>1</sup> In the Amendment filed on May 3, 2000, amended claims 10 and 14 were inadvertently numbered claims 16 and 17, respectively. The cancellation of these claims makes this error moot.



Claim	Support in Specification <sup>2</sup>
31	page 19, lines 27-29; page 40, lines 21-23; and page 41, lines 18-24
32	page 19, lines 27-29; page 40, lines 21-23 and 28-31; and page 41, lines 18-24
33	page 19, lines 27-29; page 40, lines 21-23 and 28-31; and page 41, lines 18-24
75	page 19, lines 27-29; and page 25 lines 4-12
98	page 20, line 28 through page 21, line 1
99	page 20, line 28 through page 21, line 1
100	Consensus derived from page 64, lines 1-5
101	Consensus derived from page 64, lines 1-5 page 64, lines 5-9
102	Consensus derived from page 64, lines 1-5 page 64, lines 9-12
103	page 64, lines 1-5
104	page 64, lines 5-9
105	page 64, lines 9-12
106	page 22, lines 20-26
107	page 22, lines 20-26
108	page 22, lines 20-26


After entry of the present amendment, claims 31-39, 75, and 98-108 will be pending in the present application. Attached hereto as Exhibit A is a list of the claims as pending following the entry of the instant amendment.

**The Rejection under 35 U.S.C. § 112, Second Paragraph, Should Be Withdrawn**

Claims 31, 32, and 75 are rejected as being dependent on non-elected claims. The claims have been rewritten in independent form. Applicants respectfully request that the rejection be withdrawn.

---

<sup>2</sup> The page numbers cited in this response refer to pages in the substitute specification of May 3, 2000.



**The Objections to the Claims Should Be Withdrawn**

Claims 33-39 have been objected to as being dependent upon a base claim, specifically claim 31, that has been rejected under 35 U.S.C. § 112, second paragraph.

Claim 33 has been rewritten in independent form. In view of the amendment to claim 33, Applicants respectfully request that the objection to claim 33 be withdrawn.

Further, in view of Applicants' belief that claim 31, as amended, conforms with 35 U.S.C. § 112, second paragraph, Applicants respectfully request that the objection to claims 34-39, which depend from claim 31, be withdrawn.


**CONCLUSION**

Applicants respectfully request that the amendments and remarks above be entered and made of record in the present application. Applicants respectfully submit that all pending claims fully meet all statutory requirements for patentability. Action for issuance is respectfully requested.

If any outstanding issues remain, Applicants respectfully request that the Examiner call the undersigned to discuss such issues.

Respectfully submitted,

Date March 28, 2001

  
Geraldine F. Baldwin 31,232  
(Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures